Blood Choline and its Meaning in Psychiatric and Neurologic Disease States

  • I. Hanin
  • D. G. Spiker
  • A. G. Mallinger
  • U. Kopp
  • J. M. Himmelhoch
  • J. F. Neil
  • D. J. Kupfer
Part of the Advances in Behavioral Biology book series (ABBI, volume 25)


The involvement of central cholinergic mechanisms has been implicated in a variety of neurologic disease states. These include such syndromes as tardive dyskinesia (11,17,28,32,62), Huntington’s disease (3-5,13,17,18,26,33,49,59,72,84,85,87,90), Friedreich’s ataxia (6,47), presenile dementia of Alzheimer’s type (10,14-16,25,63,64,69,77,89), and Gilles de laTourette’s disease (31,35,66). In all these syndromes a reduction in normal cholinergic activity has been implicated. As a result, attempts have been initiated over the past five years, with variable success, to alleviate some of the associated symptoms, using agents shown in animal experiments to be effective cholinomimetic agents (8). To date, however, use of direct cholinergic agonists and/or antagonists in the treatment of various neurologic, and particularly psychiatric disorders, is still in the experimental phase; such agents have not yet superceded conventionally used psychotherapeutic agents.


Lithium Treatment Neuropsychiatric Disease Brain Acetylcholine Blood Bank Donor Psychotherapeutic Agent 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Aquilonius, S.M., Schuberth, J. and Sundwall, A. (1970): IN Drugs and Cholinergic Mechanisms in the CNS (eds) E. Heilbronn and A. Winter, Research Institute of National Defence, Stockholm, pp. 399–410.Google Scholar
  2. 2.
    Aquilonius, S.M. and Eckernas, S.A. (1976): J. Neurochem. 27:317–318.CrossRefGoogle Scholar
  3. 3.
    Aquilonius, S.M. and Eckernas, S.A. (1977): Neurology 27:887.CrossRefGoogle Scholar
  4. 4.
    Barbeau, A. (1978): J. Canad. Sci. Neurol. (French) 5:157–160.Google Scholar
  5. 5.
    Barbeau, A. (1978): New Eng. J. Med. 299:200–201.Google Scholar
  6. 6.
    Barbeau, A. (1978): J. Canad. Sci. Neurol. (French) 5:161–165.Google Scholar
  7. 7.
    Barbeau, A., Growdon, J.G. and Wurtman, R.J. (eds)(1979): IN Nutrition and the Brain, Vol. 5, Choline and Lecithin in Brain Disorders, Raven Press, New York.Google Scholar
  8. 8.
    Berger, P.A., Davis, K.L. and Hollister, L.E. (1979): IN Brain Acetylcholine and Neuropsychiatric Disease (eds) K.L. Davis and P.A. Berger, Plenum Press, New York, pp. 15–32.CrossRefGoogle Scholar
  9. 9.
    Bowers, M.B. Jr., Goodman, E. and Sim, O.M. (1964): J. Nerv. Ment. Dis. 138:383–389.CrossRefGoogle Scholar
  10. 10.
    Boyd, W.D., Graham-White, J., Blackwood, G., Glen, I. and McQueen, J. (1977): Lancet 2:711.CrossRefGoogle Scholar
  11. 11.
    Casey, D.E. (1977): Dis. Nerv. Syst. 38:7–15.Google Scholar
  12. 12.
    Collard, J., Lecoq, R. and Demaret, A. (1965): Acta Neurol. Psychiat. Belg. 65:122–126.Google Scholar
  13. 13.
    Coyle, J.T., Schwarcz, R., Bennett, J.P. and Campochiaro, P. (1977): Prog. Neuro-Psychopharmacol. 1:13–20.CrossRefGoogle Scholar
  14. 14.
    Davies, P. (1979): Brain Res. 171:319–327.CrossRefGoogle Scholar
  15. 15.
    Davies, P. and Verth, A.W. (1978): Brain Res. 13:385–392.Google Scholar
  16. 16.
    Davis, K.L. and Yesavage, J.A. (1978): IN Brain Acetylcholine and Neuropsychiatric Disease (eds) K.L. Davis and P.A. Berger, Plenum Press, New York, pp. 205–213.Google Scholar
  17. 17.
    Davis, K.L., Hollister, L.E., Barchas, J.D. and Berger, P.A. (1976): Life Sci. 19:1507–1516.CrossRefGoogle Scholar
  18. 18.
    Davis, K.L., Berger, P.A., Hollister, L.E. and Barchas, J.D. (1978): Life Sci. 22:1865–1872.CrossRefGoogle Scholar
  19. 19.
    Davis, K.L., Hollister, L.E. and Berger, P.A. (1979): Amer. J. Psychiat. 136:1581–1584.Google Scholar
  20. 20.
    Davis, K.L., Berger, P.A. and Hollister, L.E. (1979): IN Nutrition and the Brain, Vol. 5, Choline and Lecithin in Brain Disorders (eds) A. Barbeau, J.G. Growdon and R.J. Wurtman, Raven Press, New York, pp. 305–316.Google Scholar
  21. 21.
    Domino, E.F. (1979): IN Brain Acetylcholine and Neuropsychiatric (eds) K.L. Davis and P.A. Berger, Plenum Press, New York, pp. 63–74.CrossRefGoogle Scholar
  22. 22.
    Domino, E.F., Mathews, B., Tait, S.K., Demetriou, S.K. and Fucek, F. (1980): this volume.Google Scholar
  23. 23.
    Dorus, E., Pandey, G.N., Shaughnessy, R., Gaviria, M., Val, Ericksen, S. and Davis, J.M. (1979): Science 205:932–933CrossRefGoogle Scholar
  24. 24.
    El-Yousef, M.K., Janowsky, D.S., Davis, J.M. and Rosenblatt, J.E. (1973): Brit. J. Addict. 68:321–325.CrossRefGoogle Scholar
  25. 25.
    Etienne, P., Gauthier, S., Dastoor, D., Collier, B. and Ratner, J. (1979): IN Nutrition and the Brain, Vol. 5, Choline and Lecithin in Brain Disorders (eds) A. Barbeau, J.G. Growdon and R.J. Wurtman, Raven Press, New York, pp. 389–396.Google Scholar
  26. 26.
    Fahn, S., Mishkin, M.M. and Hofman, R.R. (1973): IN Advanced Neurology (eds) A. Barbeau, T.N. Chase and G.W. Paulson, Raven Press, New York, pp. 531–537.Google Scholar
  27. 27.
    Gelenberg, A.J., Doller-Wojcik, J.C. and Growdon, J.H. (1979):Amer. J. Psychiat. 136:772–776.Google Scholar
  28. 28.
    Gerlach, J., Reisby, N. and Randrup, A. (1974): Psychopharmacologia 34:21–35.CrossRefGoogle Scholar
  29. 29.
    Gershon, S. and Shaw, F.H. (1961): Lancet 1:1371–1374.CrossRefGoogle Scholar
  30. 30.
    Glen, A.I.M., Ongley, G.C. and Robinson, K. (1968): Lancet 2 241–243.CrossRefGoogle Scholar
  31. 31.
    Gonge, M. and Barbeau, A. (1977): Union Med. Canad. 106:559–570.Google Scholar
  32. 32.
    Growdon, J.H., Cohen, E.L. and Wurtman, R.J. (1977): Ann. Neurol. 1:418–422.CrossRefGoogle Scholar
  33. 33.
    Growdon, J.H., Hirsch, M.J., Wurtman, R.J. and Wiener, W. (1977): New Eng. J. Med. 297:524–527.CrossRefGoogle Scholar
  34. 34.
    Growdon, J.H., Gelenberg, A.J., Doller, J., Hirsch, M.J. and Wurtman, R.J. (1978): New Eng. J. Med. 298:1029–1030.Google Scholar
  35. 35.
    Hanin, I. (1979): IN Brain Acetylcholine and Neuropsychiatric Disease (eds) K.L. Davis and P.A. Berger, Plenum Press, New York, pp. 75–86.CrossRefGoogle Scholar
  36. 36.
    Hanin, I. and Schuberth, J. (1974): J. Neurochem. 23:819–824.CrossRefGoogle Scholar
  37. 37.
    Hanin, I. and Skinner, R.F. (1975): Anal. Biochem. 66:568–583.CrossRefGoogle Scholar
  38. 38.
    Hanin, I., Kopp, U., Spiker, D.G., Neil, J.F., Shaw, D.H. and Kupfer, D.J. (1980): Psychiat. Res. 3:345–355.CrossRefGoogle Scholar
  39. 39.
    Hanin, I., Merikangas, J.R., Merikangas, K.R. and Kopp, U. (1979): New Eng. J. Med. 301:661–662.Google Scholar
  40. 40.
    Hesketh, J.E., Glen, A.I.M. and Reading, H.W. (1977): J. Neurochem., 28:1401–1402.CrossRefGoogle Scholar
  41. 41.
    Hokin-Neaverson, M., Spiegel, D.A. and Lewis, W.C. (1974): Life Sci. 15:1739–1748.CrossRefGoogle Scholar
  42. 42.
    Hollister, L.E., Jenden, D.J., Amaral, J.R.D., Barchas, J.D., Davis, K.L. and Berger, P.A. (1978): Life Sci. 23:17–22.CrossRefGoogle Scholar
  43. 43.
    Janowsky, D.S., El-Yousef, M.K. and Davis, J.M. (1974): Psychosomat. Med. 36:248–257.Google Scholar
  44. 44.
    Jenden, D.J. (1979): IN Brain Acetylcholine and Neuropsychiatric Disease (eds) K.L. Davis and P.A. Berger, Plenum Press, New York, pp. 483–514.CrossRefGoogle Scholar
  45. 45.
    Jonsson, L.E., Schuberth, J. and Sundwall, A. (1969); Life Sci. 8:977–981.CrossRefGoogle Scholar
  46. 46.
    Jope, R.S., Jenden, D.J., Ehrlich, B.E. and Diamond, J.M. (1978) New Eng. J. Med. 299:833–834.Google Scholar
  47. 47.
    Kark, R.A.P., Rodriguez-Budelli, M., Blass, J.P. and Spence, M.A. (1979): IN Brain Acetylcholine and Neuropsychiatric Disease ‚(eds) K.L. Davis and P.A. Berger, Plenum Press, New York, pp. 143–153.CrossRefGoogle Scholar
  48. 48.
    Klaver, M.M., Flentge, F., Nienhus-Kuiper, H.E. and Praag, H.M. (1979): Life Sci. 24:231–236.CrossRefGoogle Scholar
  49. 49.
    Klawans, H.L. and Rubovits, R. (1972): Neurology 22:107–116.CrossRefGoogle Scholar
  50. 50.
    Lee, G., Lingsch, C., Lyle, P.T. and Martin, K. (1974): Brit. J. Clin. Pharmacol. 1:365–370.Google Scholar
  51. 51.
    Lingsch, C. and Martin, K. (1976): Brit. J. Pharmacol. 57: 323–327.CrossRefGoogle Scholar
  52. 52.
    Maas, J.W. and Landis, D.H. (1968): J. Pharmacol. Exp. Ther. 163:147–162.Google Scholar
  53. 53.
    Mallinger, A.G., Kupfer, D.J., Poust, R.I. and Hanin, I. (1975): Clin. Pharmacol. Ther. 18:467–474.Google Scholar
  54. 54.
    Mallinger, A.G., Mallinger, J.E., Himmelhoch, J.M., Neil, J.F. and Hanin, I. (1980): Psychopharmacology 68:249–255.CrossRefGoogle Scholar
  55. 55.
    Martin, K. (1974): IN Drugs and Transport Processes (ed) B.H. Callingham, MacMillan, London, pp. 275–286.Google Scholar
  56. 56.
    Milstoc, M., Teodoru, C.V., Fieve, R.R. and Kumbaraci, T. (1975) Dis. Nerv. Syst. 36:197–199.Google Scholar
  57. 57.
    Modestin, J., Hunger, J. and Schwartz, R.B. (1973): Arch. Psychiat. Nervenkr. 218:67–77.CrossRefGoogle Scholar
  58. 58.
    Naylor, G.J., Dick, D.A.T., Dick, E.G., LePoidevin, D. And Whyte, S.F. (1973): Psychol. Med. 3:502–508.CrossRefGoogle Scholar
  59. 59.
    Nutt, J.G., Rosin, A. and Chase, T.N. (1978): Neurology 28: 1061–1064.CrossRefGoogle Scholar
  60. 60.
    Ostrow, D.G., Pandey, G.N., Davis, J.M., Hurt, S.W. and Tosteson D.C. (1978): Amer. J. Psychiat. 135:1070–1078.Google Scholar
  61. 61.
    Pandey, G.N., Dorus, E., Davis, J.M. and Tosteson, D.C. (1979): Arch. Gen. Psychiat. 36:902–908.CrossRefGoogle Scholar
  62. 62.
    Penovich, P., Morgan, J.P., Kerzner, B., Karch, F. and Goldblatt, D. (1978): JAMA 239:1997–1998.CrossRefGoogle Scholar
  63. 63.
    Perry, E.K., Gibson, P.H., Blessed, G., Perry, R.H. and Tomlinson, B.E. (1977): J. Neurol. Sci. 34:247–265.CrossRefGoogle Scholar
  64. 64.
    Perry, E.K., Perry, R.H., Blessed, G. and Tomlinson, B.E. (1977) Lancet 1:189.CrossRefGoogle Scholar
  65. 65.
    Pfeiffer, C.C. and Jenney, E.H. (1957): Ann. N.Y. Acad. Sci. 66:753–764.CrossRefGoogle Scholar
  66. 66.
    Pinta, E.R. (1977): Dis. Nerv. Syst. 38:214–215.Google Scholar
  67. 67.
    Rehavi, M., Maayani, S. and Sokolovsky, M. (1977): Biochem Pharmacol. 26:1559–1567.CrossRefGoogle Scholar
  68. 68.
    Richelson, E. (1979): Psychiat. Ann. 9: (4/April).Google Scholar
  69. 69.
    Reisine, T.D., Yamamura, H.I., Bird, E.D., Spokes, E. and Enna, S.J. (1978): Brain Res. 159:477–481.CrossRefGoogle Scholar
  70. 70.
    Rowntree, D.W., Nevin, S. and Wilson, A. (1950): J. Neurol. Neurosurg. Psychiat. 13:47–62.CrossRefGoogle Scholar
  71. 71.
    Rybakowski, J., Frazer, A., Mendels, J. and Ramsey, T.A. (1978): Commun. Psychopharmacol. 2:99–104.Google Scholar
  72. 72.
    Sadeh, M. and Brahman, J. (1979): Israel J. Med. Sex. 15:288.Google Scholar
  73. 73.
    Sayers, A.C. and Burki, H.R. (1976): J. Pharm. Pharmacol. 28: 252–253.CrossRefGoogle Scholar
  74. 74.
    Schanberg, S.M., Breese, G.R., Schildkraut, J.J., Gordon, E.K. and Kopin, I.J. (1968): Biochem. Pharmacol. 17:2006–2008.CrossRefGoogle Scholar
  75. 75.
    Schanberg, S.M., Schildkraut, J.J., Breese, G.R. and Kopin, I.J. (1968): Biochem. Pharmacol. 17:247–254.CrossRefGoogle Scholar
  76. 76.
    Schuberth, J. and Jenden, D.J. (1975): Brain Res. 84:245–256.CrossRefGoogle Scholar
  77. 77.
    Smith, CM. and Swase, M. (1979): Lancet 1:42.CrossRefGoogle Scholar
  78. 78.
    Snyder, S.H. and Yamamura, H.I. (1977): Arch. Gen. Psychiat. 34:236–239.CrossRefGoogle Scholar
  79. 79.
    Spitzer, R.L., Endicott, J. and Robins, E. (1978): Arch. Gen. Psychiat. 35:773–782.CrossRefGoogle Scholar
  80. 80.
    Stafford, R.J. and Fann, W.E. (1977): Dis. Nerv. Syst. 38:3–6.Google Scholar
  81. 81.
    Stavinoha, W.B., Modak, A.T. and Bowden, C.L. (1977): Soc. Neurosci. Abst. 3;1329Google Scholar
  82. 82.
    Szentistvanyi, I. (1978): Acta Biol. Acad. Sci. Hung. 29: 101–119.Google Scholar
  83. 83.
    Tamminga, C., Smith, R.C., Chang, S., Haraszti, J.S. and Davis, J.M. (1976): Lancet 2:905.CrossRefGoogle Scholar
  84. 84.
    Tarsy, D. and Bralower, M. (1977): Arch. Neurol. 34:756–758.CrossRefGoogle Scholar
  85. 85.
    Tarsy, D., Leopold, N. and Sax, D.S. (1974): Neurology 24: 28–33.CrossRefGoogle Scholar
  86. 86.
    Van Andel, H. (1959): IN Neuropsychopharmacology (eds) P.B. Bradley, P. Deniker and C. Raduoco-Thomas, Amsterdam, pp. 701–703.Google Scholar
  87. 87.
    Walker, J.E., Hochn, M., Sears, E. and Lewis, J. (1973): Lancet 1:1512.CrossRefGoogle Scholar
  88. 88.
    Welch, M.J., Markham, CH. and Jenden, D.J. (1976): J. Neurol. Neurosurg. Psychiat. 39:367–374.CrossRefGoogle Scholar
  89. 89.
    White, P., Goodhardt, M.J., Keet, J.P., Hiley, CP., Carasco, L.H., Williams, I.E.I, and Bowen, D.M. (1977): Lancet 1: 668–671.CrossRefGoogle Scholar
  90. 90.
    Yamamura, H.I., Wastek, G.J. and Hruska, R.E. (1979): IN Brain Acetylcholine and Neuropsychiatric Disease (eds) K.L. Davis and P.A. Berger, Plenum Press, New York, pp. 155–174.CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1981

Authors and Affiliations

  • I. Hanin
    • 1
  • D. G. Spiker
    • 1
  • A. G. Mallinger
    • 1
  • U. Kopp
    • 1
  • J. M. Himmelhoch
    • 1
  • J. F. Neil
    • 1
  • D. J. Kupfer
    • 1
  1. 1.Western Psychiatric Institute and Clinic Department of Psychiatry, School of MedicineUniversity of Pittsburgh PittsburghPennsylvaniaUSA

Personalised recommendations